Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.

Publication Type:

Journal Article


Clinical neurology and neurosurgery, Volume 112, Issue 10, p.876-82 (2010)


2010, Adolescent, Adult, Antineoplastic Agents, Blood Cell Count, Center-Authored Paper, Clinical Protocols, Clinical Research Division, Disability Evaluation, DISEASE PROGRESSION, Dose-Response Relationship, Drug, Female, Humans, Injections, Intravenous, Male, Middle Aged, MITOXANTRONE, Multiple Sclerosis, Patient Compliance, Patient Dropouts, RECURRENCE, Research Trials Office Core Facility - Biostatistics Service, Retrospective Studies, Safety, Shared Resources, Stroke Volume, United States, United States Food and Drug Administration, Young Adult


The treatment of worsening Multiple Sclerosis (MS) remains challenging. Mitoxantrone, an anthracyclines, is approved as a treatment for worsening MS. However, systematic analyses of its tolerability and effectiveness outside of controlled trials are few. Certain advantages, including easy application and simple monitoring, need to be balanced against its toxicity.